PR84072

NEWARK, Delaware, May 19, 2020 /PRNewswire=KYODO JBN/ --

QPS (

https://c212.net/c/link/?t=0&l=en&o=2807056-1&h=2695663241&u=https%3A%2F%2Fwww.qps.com%2F&a=QPS

) , a global contract research organization (CRO) that provides discovery,

preclinical, and clinical drug development services, is reinforcing its focus

on qualitative and quantitative bioanalysis of biotherapeutics. QPS announces

an expanded and upgraded fleet of high-resolution mass spectrometers (HRMS),

with the addition of three new TripleTOF(R) (

https://c212.net/c/link/?t=0&l=en&o=2807056-1&h=3365848735&u=https%3A%2F%2Fsciex.com%2Fproducts%2Fmass-spectrometers%2Fqtof-systems%2Ftripletof-systems%2Ftripletof-6600plus-system%3Futm_source%3Dadwords%2Bsearch%26utm_medium%3Dcpc%26utm_campaign%3Dportfolio%2B1%2B-%2Bquantification%26utm_term%3Dg-s-h-a-6600plus%2Bproduct%2Bpage-jun-19%26utm_content%3Dproduct%2Bpage%26gclid%3DCj0KCQjwncT1BRDhARIsAOQF9Lm1RxViDyCuPJQY69S2IzJ0rcbTSvRr2sEkeK4S_N4PBf9_lz5-VogaAkR4EALw_wcB&a=TripleTOF

) HRMS systems for GLP quantitation, two in the Newark, Delaware facility and

one in the Suzhou, China laboratory. As part of this expansion, QPS has hired

Larry Mallis, Ph.D., Director of Bioanalysis, to lead the newly merged

biotherapeutics and biomarkers Liquid Chromatography–Mass Spectrometry (LC-MS)

quantitation team in Delaware.

Photo - https://mma.prnewswire.com/media/1169522/QPS_laboratory.jpg

Photo - https://mma.prnewswire.com/media/1169523/Larry_Mallis.jpg

Logo - https://mma.prnewswire.com/media/805158/QPS_Logo.jpg

The QPS facility in Newark, Delaware, now has four high-resolution mass

spectrometers: two 6600+, one 6600, and one 5600, all of which are being used

for Good Laboratory Practice (GLP) quantitation and metabolite identification.

"QPS has been closely watching the trends in the market and we are committed to

responding to the needs of our clients by dedicating four of the five

TripleTOF(R) Ultra-Performance Liquid Chromatography–High-Resolution Mass

Spectrometry (UPLC-HRMS) systems to quantitation of oligonucleotides and intact

proteins," said John Kolman, VP, Global Head of Translational Medicine, QPS

LLC.

"This increase in capacity and capability comes at a pivotal moment for QPS in

China, as we continue our two-decades-long global effort to support the pharma

industry in developing antiviral therapeutics and/or vaccines. This has become

a higher priority in view of the new public health concerns due to the novel

coronavirus," said Yondong Zhu, VP, Head of Bioanalytical Services, QPS China.

Larry Mallis, Ph.D., leader of the newly formed team in Newark, Delaware, built

his career in the pharmaceutical industry (BMS, Wyeth, and Merck), before

moving into the CRO industry, most recently as Director of Bioanalytical

Operations at Lovelace Biomedical Research Institute. This new group now has

all the necessary LC-MS and other chromatographic technology for PK/PD

bioanalysis to support clients in drug discovery and development of rare

diseases. This group's expertise lies in the quantitation of oligonucleotides,

peptides, intact proteins, and highly hydrophilic low-molecular-weight

metabolite biomarkers by UPLC-HRMS, or by immunoaffinity UPLC-MS/MS (tandem

mass spectrometry), or by hybridization-LC-fluorescence.

ABOUT QPS HOLDINGS, LLC

Since 1995, QPS has provided discovery, preclinical, and clinical drug

development services. An award-winning leader focused on bioanalytics and

clinical trials, QPS is known for proven quality standards, technical

expertise, a flexible approach to research, client satisfaction, and turnkey

laboratories and facilities. QPS has CLIA-certified and GLP-compliant

laboratories ready to fast-track your novel coronavirus and COVID-19

RT-qPCR/QPCR and Serological Assays and vaccine development programs. For more

information, visit www.qps.com or email info@qps.com.

QPS CONTACT:

Name: Gabrielle Pastore  

Phone: +1-302-635-4290  

Email: Gabrielle.Pastore@qps.com

Source: QPS